Biocryst to Acquire Astria in $700M Deal
BioCryst Pharmaceuticals Inc. announced a cash-and-stock transaction to acquire Astria Therapeutics Inc. for approximately $700 million.
The acquisition combines BioCryst's commercialization capabilities with Astria's innovative research pipeline, strengthening its position in the rare disease and immunology market.
- The transaction values Astria shares at $8.55 in cash plus 0.59 BioCryst shares, representing a 53% premium over Astria's October 13 closing price.
- The deal signals a new era in therapies for hereditary angioedema (HAE) and allergic and immunologic disorders.
No direct quotes available in the given text.
Author's summary: BioCryst acquires Astria for $700M.